Accueil » La R&D d'Unicancer » Les publications de la R&D d'Unicancer » Communications orales et posters

Communications et posters de la R&D d'Unicancer

2016

PRODIGE 2 phase III trial neoadjuvant in rectal cancer: quality of life and results at 5 years

Pierre-Luc Etienne et al., ASCO

2016

Real-life activity of oral vinorelbine in metastatic breast cancer patients in the Unicancer ESME database

Pierre H et al., SABCS 2016

2016

Modelling relapse in patients with high-risk localised prostate cancer treated randomly in the GETUG 12 phase III trial reveals two populations of relapsing patients

C. Vicier et al., ESMO 2016

2016

Observatoire Français pur l'Etude du syndrome de Lynch OFELy: base clinico-biologique nationale et ressouces biologiques dédiées à la recherche sur le syndrome de Lynch

Christine Lasset et al., 8e assises de génétique humaine et médicale

2016

PACSA: Phase II study of pazopanib in patients with progressive recurrent or metastatic (R/M) salivary gland carcinoma (SGC).

Joel Guigay et al., ASCO 2016

2016

Osteosarcoma with several bone localisations at diagnosis: experience of the OS2006 study

Cyril Lervat et al., SIOP 2016

2016

Pazopanib in patients with progressive or metastatic (R/M) salivary gland carcinoma (SGC) : further evaluation of efficacy including tumor growth rates (TGR) analysis. H&N Unicancer Group, PACSA trial with the REFCOR

Joel Guigay et al., ESMO 2016

2016

Outcome according to elective pelvic radiotherapy in patients with high-risk localized prostate cancer: a secondary analysis of the GETUG 12 phase III randomized trial 

Blanchard P. et al, ESMO 2016

2016

Overall survival of patients with HER2-negative metastatic breast cancer treated with a first-line paclitaxel with or without bevacizumab in real-life setting: Results of a multicenter national observational study

Suzette Delaloge et al., ASCO

2016

Metastasis free survival (MFS) is a surrogate for Overall Survival (OS) in Localized Prostate Cancer (CaP).

W. Xie et al., ESMO 2016